Clinical Supply Regulatory Articles
-
The Small Biotech's Checklist For FIH Trials
8/27/2024
Getting medicine to its first patients is enormously complex with many players and moving parts. These are the critical steps.
-
The Holistic Guide To Supply Chain For Cell & Gene Therapy Startups
1/19/2023
How does the cell and gene therapy supply chain team stay ahead of the expected changes and respond at the speed the developing program expects? Supplier selection, raw materials, built-in quality, warehousing and logistics, and traceability are all covered in this article.
-
Have We Got Novel Drug Production And Compliance Timelines All Wrong?
6/13/2024
Drug developers might want to consider longer-term approaches to meeting manufacturing and regulatory requirements.
-
Survey Findings: How Are IDMP Readiness Efforts Progressing?
12/13/2024
ISO Identification of Medicinal Products (IDMP) standards were designed to harmonize the way the life sciences industry records and manages data about its products. Companies’ state of readiness to implement and harness IDMP still varies.
-
How Recce Is Delivering 5,000 Doses Per Week For Its Clinical Trials
10/25/2024
Automation and the underlying chemistry of its R327 candidate have helped the antibiotic developer reach notably high production volumes.
-
FDA Finalizes Guidance About Delaying, Denying, Limiting, Or Refusing An Inspection
7/25/2024
The FDA has finalized a guidance on the circumstances that constitute delaying, denying, limiting, or refusing a drug or device inspection. The agency also provides reasons that may cause drugs or devices to be adulterated under the FD&C Act.
-
Supplying Complex, Controversial, And Intercontinental Clinical Trials
3/13/2024
Planning a clinical supply strategy for a complicated substance, psilocybin, is tricky. It's even more tricky doing it from the other side of the planet. Here's one company's approach.
-
EMA Guideline On Clinical-Stage ATMPs Comes Into Effect: On The Verge Of Convergence?
6/19/2025
The EMA’s Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials came into effect on July 1, 2025
-
2024 Trends In FDA Observations For Sterile Drug Manufacturers
1/30/2025
This data-driven analysis of the 2024 trends in FDA observations for sterile drug manufacturers includes a comparison to the 2023 trends. Which 21 CFR 211 sections surprise you most?
-
Challenges In Manufacturing TIL For Clinical Trials
3/6/2025
Tumor-infiltrating lymphocyte cell therapy shows promise for treating solid tumors, but its complex manufacturing profile brings a unique set of issues. Here are some things to watch out for.